75 related articles for article (PubMed ID: 27383326)
1. Adverse events risk associated with angiogenesis inhibitors addition to therapy in ovarian cancer: a meta-analysis of randomized controlled trials.
Liang XJ; Shen J
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2701-9. PubMed ID: 27383326
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.
Wang H; Xu T; Zheng L; Li G
Int J Gynecol Cancer; 2018 Jun; 28(5):903-914. PubMed ID: 29561301
[TBL] [Abstract][Full Text] [Related]
3. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Lai XX; Xu RA; Yu-Ping L; Yang H
Onco Targets Ther; 2016; 9():2421-8. PubMed ID: 27143937
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
Guo C; Yan C; Qu L; Du R; Lin J
Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
[TBL] [Abstract][Full Text] [Related]
5. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.
Ye Q; Chen HL
Arch Gynecol Obstet; 2013 Sep; 288(3):655-66. PubMed ID: 23543268
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
[TBL] [Abstract][Full Text] [Related]
8. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials.
Li X; Zhu S; Hong C; Cai H
Curr Med Res Opin; 2016; 32(3):555-62. PubMed ID: 26652645
[TBL] [Abstract][Full Text] [Related]
10. Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis.
Gu B; Gao W; Chu H; Gao J; Fu Z; Ding H; Lv J; Wu Q
Medicine (Baltimore); 2016 Nov; 95(48):e3752. PubMed ID: 27902583
[TBL] [Abstract][Full Text] [Related]
11. Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
Feng Y; Huang H; Wan T; Zhang C; Tong C; Liu J
Adv Ther; 2019 Dec; 36(12):3368-3380. PubMed ID: 31599396
[TBL] [Abstract][Full Text] [Related]
12. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
[TBL] [Abstract][Full Text] [Related]
13. Does the age affect the efficacy of angiogenesis inhibitors in ovarian cancer? A meta-analysis of randomized controlled trials.
Miao H; Miao CX; Han J; Li N
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(13):3047-3053. PubMed ID: 28742202
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.
Qi WX; Shen Z; Tang LN; Yao Y
Eur J Clin Pharmacol; 2014 Aug; 70(8):893-906. PubMed ID: 24858820
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
Faruque LI; Lin M; Battistella M; Wiebe N; Reiman T; Hemmelgarn B; Thomas C; Tonelli M
PLoS One; 2014; 9(7):e101145. PubMed ID: 24988441
[TBL] [Abstract][Full Text] [Related]
17. The role of angiogenesis inhibitors in the treatment of elderly patients with advanced non-small-cell lung cancer: A meta-analysis of eleven randomized controlled trials.
Tian RH; Wu X; Liu X; Yang JW; Ji HL; Yan YJ
J Cancer Res Ther; 2016; 12(2):571-5. PubMed ID: 27461612
[TBL] [Abstract][Full Text] [Related]
18. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
Breast Cancer Res Treat; 2012 Sep; 135(2):335-46. PubMed ID: 22689092
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.
Totzeck M; Mincu RI; Rassaf T
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
